Partner Article

SCM to make US debut

Northumberland pharmaceutical firm SCM Pharma is looking to grow its presence in the US by making its debut at a major event in New York.

The firm, which offers production services to clients in the drug development and medical devices sectors, will attend the large-scale Interphex event as the company looks to roll-out its services to the North American market.

The company is hoping the exhibition will add to its recent successes, having picked-up a number of overseas contracts which have helped grow the business by over 40%.

The team from SCM Pharma will be using the global event to communicate the firm’s specialist service offerings that are aimed specifically at clinical trial and low volume commercial drug product supply.

SCM’s director Fiona Cruickshank said: “As one of the biggest events in our sector’s worldwide event calendar, Interphex provides the ideal platform for us to officially launch the business in the US and to showcase our novel capabilities.

“Given the recent interest we have received from US-based companies, particularly with regards to our ability to aseptically process radio-labelled compounds and potent products in one facility, we have very high hopes for the event.”

Interphex is one the world’s largest meeting places for those involved in drug manufacturing. It has been going for over 30 years and the event welcomes thousands of pharmaceutical and biotechnology professionals from across the globe.

SCM employs around 50 people and has worked on products linked to a number of therapeutic areas including cancer, rheumatoid arthritis, epilepsy, dermatitis, needle-free injection technology and sexual health.

This was posted in Bdaily's Members' News section by Ruth Mitchell .